Teradyne (TER) Q1 2025 Earnings Transcript

Teradyne reported Q1 revenue of $686 million and non-GAAP EPS of $0.75, both above the high end of guidance, with gross margin at 60.6% driven by favorable mix. However, management issued cautious Q2 guidance of $610 million-$680 million revenue and $0.41-$0.64 EPS, citing tariff-related uncertainty, order pushouts in auto and industrial, and no visibility beyond the second quarter. The company also lifted its share repurchase target to up to $1 billion through 2026 and highlighted AI-related test wins, including first HBM4 wafer sort and AI compute revenue.

Analysis

The market is still underestimating how much of TER’s near-term resilience is coming from mix, not demand. The company is effectively using mobile/AI-related SoC and early SLT/IST content to offset cyclical softness elsewhere, but the next leg matters more: if AI accelerator SLT moves from “first production” to repeat orders, TER gets a much higher-margin attach rate than classic ATE. That creates a favorable operating leverage setup into 2026 even if 2H25 remains choppy.

The bigger second-order read-through is that trade-policy uncertainty is changing customer behavior before it changes end demand. For capital equipment suppliers, that tends to defer orders rather than destroy them, which can create a sharp rebound once visibility improves; TER is positioning for that by cutting breakevens in Robotics and preserving buyback capacity. The $1B repurchase authorization through 2026 is not just capital return — it is a signal that management believes trough cash generation is intact even if headline revenue lags.

The weak spot is memory and robotics timing. Memory looks like a digestion phase, but the HBM4 win is strategically important because it suggests TER can regain share on next-gen performance test without needing broad market growth; the payoff is back-half 2025 and 2026, not the next quarter. Robotics is still a macro call option, but the structural restructuring reduces the need to underwrite a full-cycle recovery just to avoid losses.

Consensus is probably too focused on the conservative Q2 guide and not enough on the fact that the company is explicitly refusing to guide past it because of policy uncertainty, not because of customer loss. That distinction matters: if tariffs/trade concerns stabilize, deferred test and automation projects can re-rate quickly. The risk is that AI demand proves more upgrade-heavy than system-heavy, which would cap the multiple expansion even if revenue holds up.

Key Decisions for Investors

• Long TER on 6-12 month horizon: build on weakness near guide-driven pullbacks, targeting a re-rating into late-2025 as deferred mobile/auto/industrial orders clear. Risk/reward is attractive if AI SLT converts to repeat production orders and buybacks remain active.
• Pair trade: long TER / short a more macro-levered industrial automation name over 3-6 months. TER has more direct AI/test catalysts and a better balance-sheet backstop, while the short leg should be more exposed to capex deferrals from trade-policy uncertainty.
• Buy TER Jan-2026 call spreads rather than outright equity for a cleaner risk-defined expression of the 2H25/2026 inflection. Upside comes from repeat AI accelerator SLT, HBM4 shipments, and a rebound in deferred orders; max loss is premium.
• Add MIR only opportunistically, not as a core long: the restructuring lowers downside, but the order quality is still macro-sensitive and the re-rating depends on proving the automotive/semiconductor cross-sell is repeatable.
• Watch TER into any policy de-escalation headlines: if tariff uncertainty improves, expect a fast catch-up trade in equipment names within days to weeks as deferred capital plans get re-ordered.